Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762778 | 0.82 | IRAK4 (0.50) | IRAK4FLT3MAPK8HDAC4 | |
| SCHEMBL25521500 | 0.82 | IRAK4 (0.45) | IRAK4FLT3HDAC4 | |
| Hydrochloric Acid SCHEMBL26911778 | 0.81 | IRAK4 (0.49) | IRAK4FLT3MAPK8HDAC4 | |
| Hydrochloric Acid SCHEMBL947525 | 0.81 | IRAK4 (0.49) | IRAK4FLT3MAPK8HDAC4 | |
| SCHEMBL27201549 | 0.77 | IRAK4 (0.44) | IRAK4FLT3MAPK8PDGFRBHDAC4 | |
| SCHEMBL1914524 | 0.76 | MAPK1 (0.45) | IRAK4HPGDS | |
| SCHEMBL27201566 | 0.74 | IRAK4 (0.41) | IRAK4FLT3 | |
| SCHEMBL19385133 | 0.74 | USP30 (0.58) | FLT3HPGDSPDGFRB | |
| SCHEMBL27201472 | 0.71 | HDAC4 (0.48) | IRAK4HDAC4 | |
| SCHEMBL22145804 | 0.70 | IRAK4 (1.00) | IRAK4FLT3LCKRETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | IRAK4 1128/4885FLT3 3098/4885MAPK8 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.